Investors

    NASDAQ: STEM

      Listed on the NASDAQ Market since 1992, we are committed to       balancing our standards of scientific rigor and clinical integrity with our       corporate imperatives of value creation and long-term business       sustainability.

Corporate Profile

Driven by nearly 20 years of pioneering research and innovation, StemCells, Inc. is at the forefront of a breakthrough approach to treating human disease. We are applying our scientific and industry leadership in stem cell biology to discover, develop and commercialize novel therapeutics and enabling tools and technologies for use in stem cell-based research and drug discovery.
More >>

Learn more about What Sets Us Apart.


StemCells, Inc. has been listed on the NASDAQ Market since 1992.
CEO Podcast
11/19/10  Interview with CEO Martin McGlynn on Proposed Spinal Cord Injury Trial
Letter to Investors
May 2014  Letter to Investors from CEO Martin McGlynn
Recent News
09/04/14StemCells, Inc. to Participate at the 16th Annual Rodman & Renshaw Global Investment Conference
Management Will Present an Update on the Company's Programs, Pipeline and Operations NEWARK, Calif., Sept. 4, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that management will present at the 16th Annual Rodman & Renshaw Global Investment Conference Wednesday, September 10, at 9:10 AM EDT in the Holmes II Salon room at the New York Palace Hotel, 455 Madison Avenue, New York, NY. Management is scheduled to present an update on the Company's programs, pipeline and ope... 
Printer Friendly Version
08/12/14StemCells, Inc. Reports Second Quarter 2014 Financial Results and Provides Business Update
Conference Call to Be Hosted August 12, 2014 at 4:30 p.m. EDT NEWARK, Calif., Aug. 12, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing and commercializing novel cell-based therapeutics and tools for use in stem cell-based research and drug discovery, today provided a business update and reported financial results for the second quarter ended June 30, 2014. "The highlight for the quarter was the release of the first interim data from our ongoing... 
Printer Friendly Version
08/05/14StemCells, Inc. Announces Webcast to Discuss Second Quarter 2014 Financial Results
NEWARK, Calif., Aug. 5, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing and commercializing novel cell-based therapeutics and tools for use in stem cell-based research and drug discovery, announced today that it will release financial results for the second quarter ended June 30, 2014 after the market close on Tuesday, August 12. StemCells will host a conference call and webcast to discuss its results and an update on its business at 1:30 p.m. Pacif... 
Printer Friendly Version
07/18/14StemCells, Inc. Announces Closing of $20 Million Offering
NEWARK, Calif., July 18, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), today announced that it has closed its previously announced offering of common stock and short term warrants. The Company sold a total of 11,299,435 units to two well recognized institutional biotechnology investors and received total proceeds, net of offering expenses and placement agent fees, of approximately $18.7 million. Each unit consists of one share of common stock and a warrant to purchase 0.85 of a share o... 
Printer Friendly Version
More >>
Upcoming Events
There are currently no events scheduled.
More >>
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever StemCells, Inc. posts new information to the site. Just enter your e-mail address and click Submit.
Enter your e-mail address here:

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.
Stock Quote
STEM (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$1.30
Change (%) Stock is Down 0.12 (8.45%)
Volume1,521,629
Data as of 09/19/14 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Analyst Coverage

Click here for a list of analysts covering StemCells, Inc.

Primary IR Contact

Greg Schiffman
CFO
StemCells, Inc.
7707 Gateway Blvd
Newark, CA 94560
Phone: 510.456.4128
Fax: 650.475.3101
Contact by e-mail



Investor Tools
Print PagePrint Page
E-mail PageE-mail Page
RSS FeedsRSS Feeds
E-mail AlertsE-mail Alerts
Financial Tear SheetFinancial Tear Sheet